Review
Gastroenterology & Hepatology
Seema A. Patil, Shubha Bhat, Jimmy K. Limdi, Francis A. Farraye, Raymond K. Cross
Summary: Biosimilar medications can significantly reduce treatment costs for patients with inflammatory bowel disease. Observational studies have demonstrated similar efficacy and safety between biosimilars and biologic reference products. Shared decision-making is crucial for the successful implementation of these agents.
INFLAMMATORY BOWEL DISEASES
(2022)
Review
Biochemistry & Molecular Biology
Vishal Khatri, Ramaswamy Kalyanasundaram
Summary: This review focuses on the association between IBD and gut inflammasome, as well as recent advances in research and therapeutic strategies for IBD, discussing inflammasomes and their components, outcomes from experimental animals and human studies, inflammasome inhibitors, and developments in inflammasome-targeted therapies for IBD.
Review
Biochemistry & Molecular Biology
HyunTaek Jung, Jae Seok Kim, Keum Hwa Lee, Kalthoum Tizaoui, Salvatore Terrazzino, Sarah Cargnin, Lee Smith, Ai Koyanagi, Louis Jacob, Han Li, Sung Hwi Hong, Dong Keon Yon, Seung Won Lee, Min Seo Kim, Paul Wasuwanich, Wikrom Karnsakul, Jae Il Shin, Andreas Kronbichler
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people. Recent studies have shown that microRNAs (miRNAs) play an important role in the pathogenesis, diagnosis, and treatment of IBD.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Uma Mahadevan, Millie D. Long, Sunanda Kane, Abhik Roy, Marla C. Dubinsky, Bruce E. Sands, Russell D. Cohen, Christina D. Chambers, William J. Sandborn
Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.
Review
Gastroenterology & Hepatology
Shomron Ben-Horin, Lena Novack, Ren Mao, Jing Guo, Yue Zhao, Ruslan Sergienko, Jian Zhang, Taku Kobayashi, Toshifumi Hibi, Yehuda Chowers, Laurent Peyrin-Biroulet, Jean Frederic Colombel, Gilaad G. Kaplan, Min-hu Chen
Summary: Initiating biologic treatment early in the course of Crohn's disease may yield better treatment outcomes, while disease duration does not significantly impact results in ulcerative colitis.
Article
Medicine, General & Internal
Silvia Salvatori, Francesco Baldassarre, Michelangela Mossa, Giovanni Monteleone
Summary: Long COVID is common in patients with inflammatory bowel diseases (IBD), with fatigue being the most frequent symptom. It does not influence the frequency of IBD relapses, but is more prevalent in female patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Gastroenterology & Hepatology
Thomas M. Goodsall, Tran M. Nguyen, Claire E. Parker, Christopher Ma, Jane M. Andrews, Vipul Jairath, Robert Bryant
Summary: The study systematically identified ultrasound scoring indices for assessing inflammatory bowel disease activity, with common components including bowel wall thickness, colour Doppler imaging, and bowel wall stratification. The correlation between ultrasound indices and reference standards, as well as sensitivity, specificity, accuracy, and other properties, varied within certain ranges. However, reliability and responsiveness data were limited, and most studies were rated with unclear or high risk of bias.
JOURNAL OF CROHNS & COLITIS
(2021)
Review
Medicine, General & Internal
Katarzyna Akutko, Andrzej Stawarski
Summary: Inflammatory bowel diseases (IBD) are chronic inflammatory diseases of the digestive tract with periods of remission and relapses. The etiopathogenesis is not fully understood, leading to only symptomatic treatment. There is a constant need to search for new high safety profile therapies for IBD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Biotechnology & Applied Microbiology
Guihua Chen, Jun Shen
Summary: Inflammatory bowel disease (IBD) is a global disease with high morbidity and medical costs. Early diagnosis and intervention are crucial for controlling its progression.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2021)
Article
Gastroenterology & Hepatology
Jurij Hanzel, Peter Bossuyt, Valerie Pittet, Mark Samaan, Monika Tripathi, Wladyslawa Czuber-Dochan, Johan Burisch, Salvatore Leone, Roberto Saldana, Filip Baert, Uri Kopylov, Susanna Jaghult, Michel Adamina, Naila Arebi, Krisztina Gecse
Summary: This study aimed to develop a core outcome set for real-world studies in adult patients with inflammatory bowel disease (IBD). Candidate outcomes and outcome measures were identified through a systematic review and a modified Delphi consensus process. The international panel agreed on the final core outcome set, which will facilitate the synthesis and generation of real-world evidence.
JOURNAL OF CROHNS & COLITIS
(2023)
Editorial Material
Gastroenterology & Hepatology
Catherine Le Berre, Laurent Peyrin-Biroulet
Summary: The SPIRIT consensus group has agreed that the ultimate therapeutic goal in both CD and UC is to prevent disease impact on patients' lives, including health-related quality of life, disability, and fecal incontinence, as well as prevent complications in the short and long term, such as bowel damage, surgeries, disease extension, extraintestinal manifestations, and dysplasia or cancer. These recommendations will need to be validated in clinical studies before being implemented in disease-modification trials.
Article
Multidisciplinary Sciences
Ryan W. Gan, Diana Sun, Amanda R. Tatro, Shirley Cohen-Mekelburg, Wyndy L. Wiitala, Ji Zhu, Akbar K. Waljee
Summary: This study replicated a machine-learning model's ability to predict acute exacerbations of inflammatory bowel disease (IBD) in a nationally representative cohort, with the random forest model outperforming the logistic regression model.
Review
Medicine, General & Internal
Elisabetta Antonelli, Gabrio Bassotti, Marta Tramontana, Katharina Hansel, Luca Stingeni, Sandro Ardizzone, Giovanni Genovese, Angelo Valerio Marzano, Giovanni Maconi
Summary: This review summarizes the dermatologic manifestations occurring in patients with inflammatory bowel diseases, including specific manifestations, cutaneous disorders associated with IBDs, reactive mucocutaneous manifestations of IBDs, mucocutaneous conditions secondary to treatment, and manifestations due to nutritional malabsorption. An accurate dermatological examination is crucial in all IBD patients, especially in candidates to biologic therapies where drug-induced cutaneous reactions may be clinically relevant.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Anastasia Katsoula, Georgios Axiaris, Afroditi Mpitouli, Maria Palatianou, Angeliki Christidou, Nikolaos Dimitriadis, Andreas Nakos, Ploutarchos Pastras, Panagiotis Kourkoulis, Pantelis Karatzas, Miltiadis Moutzoukis, Charalampos Zlatinoudis, Athanasios Philippidis, Anastasia Kourikou, Georgios Kokkotis, Antonios Gklavas, Angeliki Machaira, Aikaterini Mantaka, Persefoni Talimtzi, Evaggelia Anagnostopoulou, Ioannis E. Koutroubakis, Ioannis Papaconstantinou, Georgios Bamias, Spilios Manolakopoulos, Nicoletta Mathou, Konstantina Paraskeva, Andreas Protopappas, Eftychia Tsironi, Konstantinos H. H. Katsanos, Dimitrios K. K. Christodoulou, Georgios Papatheodoridis, Georgios Michalopoulos, Georgios Theocharis, Christos Triantos, Ioannis Pachiadakis, Konstantinos Soufleris, Nikolaos Viazis, Gerassimos J. Mantzaris, Georgios Tribonias, Maria Tzouvala, Angeliki Theodoropoulou, Konstantinos Karmiris, Evanthia Zampeli, Spyridon Michopoulos, Anna-Bettina Haidich, Olga Giouleme
Summary: The aim of this study was to validate the content of IBD-Disk in a Greek cohort of IBD patients. The results showed good correlation and consistency between the scores of IBD-Disk and IBD-DI at baseline and follow-up. Female gender and extraintestinal manifestations were significantly associated with a higher IBD-Disk total score. Therefore, the Greek version of IBD-Disk was proven to be a reliable and valid tool for assessing IBD-related disability.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Gastroenterology & Hepatology
Jee Hyun Kim, Chang-Myung Oh, Jun Hwan Yoo
Summary: Obesity is common in patients with inflammatory bowel disease (IBD), especially in newly developed countries. It has been suggested that 15%-40% of IBD patients are obese, and obesity may play a role in the development of IBD. Dysfunction of mesenteric fat can worsen the inflammation in Crohn's disease and lead to the formation of strictures or fistulas. Additionally, obesity can affect the course of the disease and the response to treatment in IBD. As a result, obesity control is being proposed as a novel management approach for IBD, and this review aims to discuss the impact of obesity on IBD treatment outcomes and the current status of pharmacologic or surgical anti-obesity treatments in IBD patients.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Meeting Abstract
Oncology
Xavier Tekpli, Shom Goel, Barbro Holm, Lars-Egil Fallang, Laurens Cornelus Reitsma, Stephanie Beate Geisler, Hilde Presterud Odegard, Cathrine Bergquist Fosskaug, Ida Caroline Lindem, Manouchehr Seyedzadeh, Jonn Terje Geitung, Joana Reis, Kjell Inge Gjesdal, Unn-Cathrin Buvarp, Marie Loeng, Kristine Kleivi Sahlberg, Alina Carmen Porojnicu, Helle Kristine Skjerven, Andliena Tahiri, Shakila Jabeen, Torben Luders, Vahid Bemanian, Jorgen Jahnsen, Marianne Lyngra, Antoni Hurtado, Jason Carroll, Shiuan Chen, Vessela Kristensen, Jurgen Geisler
Letter
Medicine, General & Internal
SiljeWatterdal Syversen, Jorgen Jahnsen, Espen A. Haavardsholm
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Gastroenterology & Hepatology
Jan K. Nowak, Alex T. Adams, Rahul Kalla, Jonas C. Lindstrom, Simen Vatn, Daniel Bergemalm, Asa Keita, Fernando Gomollon, Jorgen Jahnsen, Morten H. Vatn, Petr Ricanek, Jerzy Ostrowski, Jaroslaw Walkowiak, Jonas Halfvarson, Jack Satsangi
Summary: This study uses whole-blood transcriptomic analysis to investigate the pathobiology of inflammatory bowel disease (IBD) and its potential translational implications.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Medicine, General & Internal
Marthe Kirkesaether Brun, Guro Lovik Goll, Kristin Kaasen Jorgensen, Joseph Sexton, Johanna Elin Gehin, Oystein Sandanger, Inge Christoffer Olsen, Rolf Anton Klaasen, David John Warren, Cato Mork, Tore K. Kvien, Jorgen Jahnsen, Nils Bolstad, Espen A. Haavardsholm, Silje Watterdal Syversen
Summary: This study identified several risk factors for the formation of anti-drug antibodies (ADAb) during early-phase infliximab treatment. Factors such as a diagnosis of rheumatoid arthritis, lifetime smoking, concomitant immunosuppressors, and a diagnosis of spondyloarthritis were associated with increased or reduced risk of ADAb formation. Additionally, higher disease activity and longer drug holidays increased the risk, while higher doses and serum concentrations of infliximab reduced the risk of immunogenicity.
JOURNAL OF INTERNAL MEDICINE
(2022)
Article
Rheumatology
Silje W. Syversen, Ingrid Jyssum, Anne T. Tveter, Trung T. Tran, Joseph Sexton, Sella A. Provan, Siri Mjaaland, David J. Warren, Tore K. Kvien, Gunnveig Grodeland, Lise S. H. Nissen-Meyer, Petr Ricanek, Adity Chopra, Ane M. Andersson, Grete B. Kro, Jorgen Jahnsen, Ludvig A. Munthe, Espen A. Haavardsholm, John T. Vaage, Fridtjof Lund-Johansen, Kristin K. Jorgensen, Guro L. Goll
Summary: This study evaluated the immunogenicity and safety of the standard SARS-CoV-2 vaccination regimen and a third dose in patients with immune-mediated inflammatory diseases (IMIDs) receiving immunosuppressive therapy. The results showed that IMID patients had a weaker response to the standard vaccine regimen, but the serologic response improved after receiving a third dose. These data help identify IMID patients who may benefit from a third vaccine dose.
ARTHRITIS & RHEUMATOLOGY
(2022)
Review
Gastroenterology & Hepatology
Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Jordi Guardiola, Jorgen Jahnsen, Charles Lees, Edouard Louis, Milan Lukas, Walter Reinisch, Xavier Roblin, Minyoung Jang, Han Geul Byun, Dong-Hyeon Kim, Sung Jeong Lee, Raja Atreya
Summary: This study compared the efficacy and safety of infliximab and vedolizumab in adult patients with moderate-to-severe Crohn's disease or ulcerative colitis. The results showed that infliximab had better efficacy during the induction phase and comparable efficacy during the maintenance phase compared to vedolizumab. In terms of safety, there were no significant differences between the two treatments.
BMC GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Kristin H. Bjorlykke, Jorgen Jahnsen, Jorn Brynskov, Pauliina Molander, Michael Eberhardson, Loa G. Davidsdottir, Taina Sipponen, Henrik Hjortswang, Guro Lovik Goll, Silje Watterdal Syversen, Ebbe Langholz, Kristin K. Jorgensen, Casper Steenholdt
Summary: Therapeutic drug monitoring (TDM) is widely implemented and utilized in Scandinavia to optimize biologic and thiopurine therapies in inflammatory bowel disease (IBD). However, the lack of guidelines and delayed test response time are the main barriers to the use of TDM.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Multidisciplinary Sciences
Nader Atlasy, Anna Bujko, Espen S. Baekkevold, Peter Brazda, Eva Janssen-Megens, Knut E. A. Lundin, Jorgen Jahnsen, Frode L. Jahnsen, Hendrik G. Stunnenberg
Summary: This study characterizes the immune cell compartment of the human small intestine during active Celiac disease using single cell transcriptomics. The results show altered myeloid cell transcriptomes and extensive changes in CD4(+) and CD8(+) T cell transcriptomes. In addition, a reduced population of natural intraepithelial lymphocytes is observed in Celiac disease.
NATURE COMMUNICATIONS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
C. Lund, V. A. Kristensen, I. L. Monstad, I. C. Solberg, O. Hovde, G. Huppertz-Hauss, M. Henriksen, O. Hoie, T. Bernklev, J. Jahnsen, B. Moum, M. L. Hoivik
JOURNAL OF CROHNS & COLITIS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
C. Lund, V. A. Kristensen, I. L. Monstad, I. C. Solberg, O. Hovde, G. Huppertz-Hauss, M. Henriksen, O. Hoie, T. Bernklev, J. Jahnsen, B. Moum, M. L. Hoivik
JOURNAL OF CROHNS & COLITIS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
K. Bjorlykke, M. K. Brun, M. K. Viken, G. E. Stenvik, R. A. Klaasen, J. E. Gehin, D. J. Warren, J. Sexton, E. A. Haavardsholm, J. Jahnsen, B. A. Lie, G. L. Goll, N. Bolstad, S. W. Syversen, K. K. Jorgensen
JOURNAL OF CROHNS & COLITIS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
K. Bjorlykke, J. Jahnsen, J. Brynskov, P. Molander, M. Eberhardson, L. G. Davidsdottir, T. Sipponen, H. Hjortswang, E. Langholz, K. K. Jorgensen, C. Steenholdt
JOURNAL OF CROHNS & COLITIS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
K. Bjorlykke, M. K. Brun, M. K. Viken, G. E. Stenvik, R. A. Klaasen, J. E. Gehin, D. J. Warren, J. Sexton, E. A. Haavardsholm, J. Jahnsen, B. A. Lie, G. L. Goll, N. Bolstad, S. W. Syversen, K. K. Jorgensen
JOURNAL OF CROHNS & COLITIS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
K. Bjorlykke, J. Jahnsen, J. Brynskov, P. Molander, M. Eberhardson, L. G. Davidsdottir, T. Sipponen, H. Hjortswang, E. Langholz, K. K. Jorgensen, C. Steenholdt
JOURNAL OF CROHNS & COLITIS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
K. K. Jorgensen, S. W. Syversen, I. Jyssum, A. T. Tveter, T. T. Tran, J. Sexton, S. A. Provan, S. Mjaaland, D. J. Warren, T. K. Kvien, G. Grodeland, L. S. Nissen-Meyer, P. Ricanek, A. Chopra, A. M. Andersson, G. B. Kro, J. Jahnsen, L. A. Munthe, E. A. Haavardsholm, J. T. Vaage, F. Lund-Johansen, G. L. Goll
JOURNAL OF CROHNS & COLITIS
(2022)